Table 1. Characteristics of Patients, Biospecimen Group (N = 94)a.
| Parameter | Diagnosed with CDI | Not Diagnosed with CDI | Total (Combined) | |
| tcdB+ | tcdB− | |||
| Age (years) g | 50.5 (19–69) | 57 (28–65) | 54 (23–69) | 53.5 (19–69) |
| Sex (female) | 4 (25.0%) | 10 (47.6%) | 27 (47.4%) | 41 (43.6%) |
| Underlying Disease | ||||
| Leukemia | 11 (68.8%) | 9 (42.9%) | 24 (42.1%) | 44 (46.8%) |
| Lymphoma | 2 (12.5%) | 6 (28.6%) | 18 (31.6%) | 26 (27.7%) |
| Multiple Myeloma | 1 (6.2%) | 3 (14.3%) | 4 (7.0%) | 8 (8.5%) |
| Myelodysplastic Syndrome | 2 (12.5%) | 1 (4.8%) | 9 (15.8%) | 12 (12.8%) |
| Other | 0 (0.0%) | 2 (9.5%) | 2 (3.5%) | 4 (4.3%) |
| Prior antibiotics (14 d) f | 8 (50.0%) | 7 (33.3%) | 27 (47.4%) | 42 (44.7%) |
| Conditioning Regimen Intensity | ||||
| Non-myeloablative | 1 (6.2%) | 5 (23.8%) | 10 (17.5%) | 16 (17.0%) |
| Reduced Intensity | 2 (12.5%) | 5 (23.8%) | 14 (24.6%) | 21 (22.3%) |
| Myeloablative | 13 (81.2%) | 11 (52.4%) | 33 (57.9%) | 57 (60.6%) |
| T-cell depleted graft | 10 (62.5%) | 10 (47.6%) | 22 (38.6%) | 42 (44.7%) |
| Stem cell source (cord vs. other) | 3 (18.8%) | 5 (23.8%) | 15 (26.3%) | 23 (24.5%) |
| Time to engraftment (≥14 d) b | 3 (18.8%) | 4 (19.0%) | 17 (29.8%) | 24 (25.5%) |
| Antibiotics c , d | ||||
| Vancomycin (IV) | 15 (93.8%) | 20 (95.2%) | 50 (87.7%) | 85 (90.4%) |
| Fluoroquinolone | 3 (18.8%) | 5 (23.8%) | 25 (43.9%) | 33 (35.1%) |
| Metronidazole | 14 (87.5%) | 3 (14.3%) | 13 (22.8%) | 30 (31.9%) |
| Beta-lactams e | 13 (81.2%) | 17 (81.0%) | 52 (91.2%) | 82 (87.2%) |
| Number of Specimens Collected g | ||||
| Pre-transplant | 2 (1–2) | 2 (1–2) | 1 (1–3) | 2 (1–3) |
| Post-transplant | 3 (2–6) | 3 (2–7) | 3 (2–5) | 3 (2–7) |
| Total | 16 (100.0%) | 21 (100.0%) | 57 (100.0%) | 94 (100.0%) |
a
Characteristics of patients in the observational group (N = 1144) can be found in Table S1.
b
Engraftment was defined as an absolute neutrophil count greater than 500 cells/µL for three consecutive days.
c
Assessed during inpatient allo-HSCT hospitalization, from beginning of pre-transplant up to 35 days post-transplant.
d
Antibiotics are not mutually exclusive categories and thus does not sum to 100%.
e
Beta-lactams include cephalosporins, beta-lactam/beta-lactamase combinations, and carbapenems.
f
Prior antibiotics refer to antibiotics given prior to allo-HSCT and prior to observation time, within 14 days.
g
Reported as median, with range in parentheses.